Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes

Strange, C. Clare; Manchak, Sarah M.; Petrich, Damon M.; Desai, Alisha; Haberman, Cory P.

doi:10.1002/cl2.1215

Cited by 7 publications

(1 citation statement)

References 91 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After systematically reviewing 20 CLS-based MOUD studies, Strange and colleagues found that provision of MOUD in these settings was associated with a significantly reduced the risk of non-fatal opioid overdose following release but not with reduced risk of fatal overdose or recidivism. The authors suggested the null effect on fatal overdoses could be due to difficulty in accessing mortality records [ 14 ]. and highlighted the need for more rigorous research in this area, including the use of experimental designs.…”

Section: Introductionmentioning

confidence: 99%

Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative

Lee,

Goldfeld,

Schwartz

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

The objective of this study was to estimate the associations of jail-initiated medication for opioid use disorder (MOUD) and patient navigation (PN) with opioid use disorder (OUD) at 6 months post-release. Three randomized trials (combined N = 330) were combined to assess whether MOUD (extended-release naltrexone or interim methadone) initiated prior to release from jail with or without PN would reduce the likelihood of a DSM-5 diagnosis of OUD 6 months post-release relative to enhanced treatment-as-usual (ETAU). Across the three studies, assignment to MOUD compared to ETAU was not associated with an OUD diagnosis at 6 months post-release (69% vs. 75%, respectively, OR = 0.67, 95% CI: 0.42 to 1.20). Similarly, PN compared to MOUD without PN was not associated with an OUD diagnosis (63% vs 77%, respectively, OR = 0.61, 95% CI: 0.27 to 1.53). Results underscore the need to further optimize the effectiveness of MOUD for patients initiating treatment in jail, beginning with an emphasis on post-release treatment adherence.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative

Lee,

Goldfeld,

Schwartz

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

PROTOCOL: Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes

Strange

Manchak

Haberman

et al. 2021

Campbell Systematic Reviews

Self Cite

View full text Add to dashboard Cite

Background The overlap between criminal justice system involvement and drug use is well‐documented, and criminal justice agencies have been particularly overwhelmed by the recent opioid epidemic. Treating opioid (and other substance) addiction as a means to reduce risk for future criminality and improve public safety is inherently a responsibility for the criminal justice system. In turn, the criminal justice system has a responsibility to manage and treat addiction among the individuals under its purview. Policy recommendations place emphasis on the use of medication‐assisted treatments (MAT) as a front‐line defense among correctional populations, because its efficacy and effectiveness has been well‐established in other contexts. Despite this, criminal justice agencies have been reluctant or slow to do so. Objectives The current review will provide criminal justice and substance use treatment decision‐makers with information regarding the efficacy and effectiveness of opioid‐specific MAT on offending and overdose outcomes. Specifically, the authors will address the following research questions: Do opioid‐specific MATs reduce the frequency or likelihood of criminal justice outcomes, as defined by official or self‐reported indices of criminal reconviction or rearrest, revocation of community supervision, mandated treatment failure, and specialized court docket failure? Do opioid‐specific MATs reduce the frequency of opioid overdose among individuals with current or prior self‐reported or official record of criminal justice system involvement? Inclusion Criteria Studies were required to use strong quasi‐experimental or randomized experimental designs. All studies used individual level unit of analysis and examined adults and adolescents who are male, female, or nonbinary and racially/ethnically diverse, with current opioid use and who have current or prior criminal justice involvement. Studies had to prospectively test the effects of heroin and methadone maintenance, buprenorphine, or naltrexone on criminal conviction, arrest, revocation of community supervision, technical probation or parole violation, mandated treatment failure, and specialized court docket failure. Overdose outcomes were also examined for samples in criminal justice settings such as jails, prisons, probation, and parole. Search Strategy and Data Collection This review builds upon a prior review conducted by Egli et al. (2009) and examined studies meeting the inclusion criteria above published between 1960 and October 31, 2020. The following platforms and databases (in parentheticals) were used: EBSCOhost (Criminal Justice Abstracts, SocINDEX with Full Text, Legal Collection, Wilson Omnifile, PsycINFO, Social Work Abstracts, and Women's Studies International [includes grey literature]); ProQuest (Criminal Justice Database, PAIS [includes grey literature], Dissertations and Theses Global [includes grey literature]); Gale (Expanded Academic ASAP, Opposing Viewpoints Resource Center); FirstSearch (GPO Monthly Catalog, PapersFirst [include...

show abstract

Impact of opioid maintenance therapy in the community on re-incarceration in individuals with opioid use disorder—A linked cohort study

Paola,

Pavel,

Tatiana

et al. 2024

Journal of Substance Use and Addiction Treatment

View full text Add to dashboard Cite

Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes

Cited by 7 publications

References 91 publications

Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative

Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative

PROTOCOL: Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes

Impact of opioid maintenance therapy in the community on re-incarceration in individuals with opioid use disorder—A linked cohort study

Contact Info

Product

Resources

About